Enfusion Files Registration Statement with SEC for Proposed Initial Public Offering - Enfusion

This site uses cookies to improve your experience.
We’ll assume you’re okay with this, but you can opt out if you wish.

Back to In The News

Enfusion Files Registration Statement with SEC for Proposed Initial Public Offering

Sep.17.2021

Share

Copy

Media Contact

For media inquiries, please contact:

media@enfusion.com

NEW YORK / LONDON / HONG KONG, September 17, 2021 – Enfusion, Inc. ("Enfusion"), a leading provider of cloud-based investment management software and services, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Enfusion intends to list its common stock on the New York Stock Exchange under the ticker symbol “ENFN.”

Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC will act as lead book-running managers for the proposed offering, with BofA Securities, Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C., Stifel, Nicolaus & Company, Incorporated and Piper Sandler & Co. acting as other bookrunners.

The offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, New York 10014, Attn: Prospectus Department, by email: prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Enfusion

Enfusion's investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one cloud-native system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility, and powering growth.  Enfusion partners with 600+ investment managers from nine global offices spanning four continents.

Media Contacts:

Prosek Partners
Bea Broderick
pro-enfusion@prosek.com

Investor Relations Contact:

Gain a clear advantage.

Talk to Us